A.M. Vitals: Bristol-Myers Paying $2.5 Billion For Inhibitex

By

Katherine Hobson

Jan 9, 2012 8:51 am ET

Hepatitis C Deal: Bristol-Myers Squibb is buying Inhibitex, which has a hepatitis C drug in development, for $26 per share in cash, or about $2.5 billion, the WSJ reports. Like Bristol-Myers, Inhibitex is developing a drug belonging to the so-called nucleotides class. A Bristol executive tells the WSJ Inhibitex’s drug could combine with Bristol’s drugs to become “a very powerful regimen” for use against hepatitis C, the paper reports …